# Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis

> **NCT06691217** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Vascular Inflammation
- ASCVD
- ASCVD Management

## Interventions

- **DRUG:** CANAKINUMAB (ILARIS®)
- **DRUG:** Saline (NaCl 0,9 %) (placebo)

## Key facts

- **NCT ID:** NCT06691217
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-24
- **Primary completion:** 2029-01-01
- **Final completion:** 2030-04-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06691217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06691217, "Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT06691217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*